-transparent.png){kind=logo}
Antibody- and gene-directed enzyme prodrug therapy are two-step targeting strategies designed to improve the selectivity of antitumour agents. The approaches are based on the activation of specially designed prodrugs by antibody-enzyme conjugates targeted to tumour-associated antigens (ADEPT) or by enzymes expressed by exogenous genes in tumour cells (GDEPT). Herein the design, synthesis, physico-chemical and biological properties, kinetics and clinical trials of the prodrugs and the enzymes carboxypeptidase G2 and nitroreductase are reviewed for ADEPT and GDEPT.
Related Publications
I Niculescu-Duvaz, and
F Friedlos, and
D Niculescu-Duvaz, and
L Davies, and
C J Springer
July 1995,
Anti-cancer drug design,
I Niculescu-Duvaz, and
F Friedlos, and
D Niculescu-Duvaz, and
L Davies, and
C J Springer
December 1999,
Bioorganic & medicinal chemistry letters,
I Niculescu-Duvaz, and
F Friedlos, and
D Niculescu-Duvaz, and
L Davies, and
C J Springer
January 2002,
Acta biochimica Polonica,
I Niculescu-Duvaz, and
F Friedlos, and
D Niculescu-Duvaz, and
L Davies, and
C J Springer
December 1996,
Anti-cancer drug design,
I Niculescu-Duvaz, and
F Friedlos, and
D Niculescu-Duvaz, and
L Davies, and
C J Springer
September 1996,
International journal of oncology,
I Niculescu-Duvaz, and
F Friedlos, and
D Niculescu-Duvaz, and
L Davies, and
C J Springer
October 1990,
Biochemical Society transactions,
I Niculescu-Duvaz, and
F Friedlos, and
D Niculescu-Duvaz, and
L Davies, and
C J Springer
January 1993,
Advances in pharmacology (San Diego, Calif.),
I Niculescu-Duvaz, and
F Friedlos, and
D Niculescu-Duvaz, and
L Davies, and
C J Springer
October 2006,
Expert review of anticancer therapy,
I Niculescu-Duvaz, and
F Friedlos, and
D Niculescu-Duvaz, and
L Davies, and
C J Springer
November 2004,
Expert opinion on biological therapy,
I Niculescu-Duvaz, and
F Friedlos, and
D Niculescu-Duvaz, and
L Davies, and
C J Springer
January 2000,
Advances in experimental medicine and biology,
